Results 191 to 200 of about 150,657 (357)

Lewis‐X‐Containing Triterpenoid Saponins Inhibit DC‐SIGN‐ and L‐SIGN‐Mediated Transfer of HIV‐1 Infection

open access: yesChemistry – A European Journal, EarlyView.
The convergent synthesis of Lewis‐X‐containing betulinic acid and echinocystic acid saponins (1 and 2) is presented. The synthetic saponins were shown to inhibit, at the low micromolar range, the DC‐SIGN‐ and L‐SIGN‐mediated transfer of HIV‐1 infection to CD4‐positive cells, whereas free Lewis‐X, aglycones, and structurally similar triterpenoid ...
Oscar Javier Gamboa Marin   +5 more
wiley   +1 more source

DapPep: Domain Adaptive Peptide-agnostic Learning for Universal T-cell Receptor-antigen Binding Affinity Prediction [PDF]

open access: yesarXiv
Identifying T-cell receptors (TCRs) that interact with antigenic peptides provides the technical basis for developing vaccines and immunotherapies. The emergent deep learning methods excel at learning antigen binding patterns from known TCRs but struggle with novel or sparsely represented antigens.
arxiv  

CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. [PDF]

open access: yesFront Immunol, 2018
van Balen P   +10 more
europepmc   +1 more source

HL-A histocompatibility antigens and cutaneous reactions to practolol

open access: hybrid, 1976
S Wadskov   +4 more
openalex   +2 more sources

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy